Weekly Investment Analysts’ Ratings Updates for ACADIA Pharmaceuticals (ACAD)

Posted by Jessica Moore on Jan 22nd, 2026

Several brokerages have updated their recommendations and price targets on shares of ACADIA Pharmaceuticals (NASDAQ: ACAD) in the last few weeks:

1/11/2026 – ACADIA Pharmaceuticals was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
1/6/2026 – ACADIA Pharmaceuticals had its price target raised by analysts at UBS Group AG from $35.00 to $40.00. They now have a “buy” rating on the stock.
1/6/2026 – ACADIA Pharmaceuticals had its price target raised by analysts at Citigroup Inc. from $33.00 to $36.00. They now have a “buy” rating on the stock.
1/5/2026 – ACADIA Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $34.00 price target on the stock.
1/3/2026 – ACADIA Pharmaceuticals was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
12/29/2025 – ACADIA Pharmaceuticals had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
12/22/2025 – ACADIA Pharmaceuticals had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
12/16/2025 – ACADIA Pharmaceuticals was given a new $37.00 price target on by analysts at Stifel Nicolaus.
12/16/2025 – ACADIA Pharmaceuticals was given a new $37.00 price target on by analysts at Piper Sandler.
12/15/2025 – ACADIA Pharmaceuticals had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
12/15/2025 – ACADIA Pharmaceuticals had its price target raised by analysts at HC Wainwright from $32.00 to $37.00. They now have a “buy” rating on the stock.
12/11/2025 – ACADIA Pharmaceuticals had its price target raised by analysts at Stifel Nicolaus from $24.00 to $25.00. They now have a “hold” rating on the stock.
12/8/2025 – ACADIA Pharmaceuticals had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
12/4/2025 – ACADIA Pharmaceuticals had its “buy” rating reaffirmed by analysts at UBS Group AG. They now have a $35.00 price target on the stock.
12/2/2025 – ACADIA Pharmaceuticals had its price target raised by analysts at Mizuho from $24.00 to $29.00. They now have a “neutral” rating on the stock.
12/1/2025 – ACADIA Pharmaceuticals had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
11/24/2025 – ACADIA Pharmaceuticals had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.

Insider Buying and Selling at ACADIA Pharmaceuticals

In other news, Director James M. Daly sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $22.37, for a total value of $671,100.00. Following the transaction, the director owned 4,041 shares in the company, valued at approximately $90,397.17. This trade represents a 88.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider James Kihara sold 4,084 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $23.69, for a total value of $96,749.96. Following the sale, the insider directly owned 25,058 shares in the company, valued at approximately $593,624.02. The trade was a 14.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 44,346 shares of company stock worth $1,010,957 over the last 90 days. Corporate insiders own 26.50% of the company’s stock.

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.